Review article| Volume 246, P187-189, March 2020

EBCOG position statement: Gender neutral HPV vaccination for young adults

Published:January 16, 2020DOI:


      Human Papilloma Virus (HPV) has been implicated in the initiation of several types of cancers in both females and males. Therefore, it is imperative that national immunization programs should ensure that both young women and young men receive full immunization for herd immunity in their teenage years. A recent review confirmed that vaccination of boys and girls would be most cost-effective under the circumstances that both individual costs and coverage are low. By doing so, it would be possible to reduce the incidence of HPV-related malignancies to a large extent at later age in both sexes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • WHO-IARC
        List of classifications by cancer sites with sufficient or limited evidence in humans, Volumes 1 to 121.
        • Castellsague X.
        • Alemany L.
        • Quer M.
        • Halec G.
        • Quiros B.
        • Tous S.
        • et al.
        HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients.
        J Natl Cancer Inst. 2016; 108: djv403
        • Office for National Statistics
        Cancer registration statistics, England.
        • St Laurent J.
        • Luckett R.
        • Feldman S.
        HPV vaccination and the effects on rates of HPV-related cancers.
        Curr Probl Cancer. 2018; 42: 493-506
        • Garland S.M.
        • Cornall A.M.
        • Brotherton J.M.L.
        • Wark J.D.
        • Malloy M.J.
        • Tabrizi S.N.
        • et al.
        Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
        Vaccine. 2018; 36: 3221-3230
        • Sheikh S.
        • Biundo E.
        • Courcier S.
        • Damm O.
        • Launay O.
        • Maes E.
        • et al.
        A report on the status of vaccination in Europe.
        Vaccine. 2018; 36: 4979-4992
        • Brisson M.
        • Bénard É
        • Drolet M.
        • Bogaards J.A.
        • Baussano I.
        • Vänskä S.
        • et al.
        Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
        Lancet Publ Health. 2016; 1: e8-e17
      1. M. Zaffran, blog, (entered 11 nov 2018).

        • Soe N.N.
        • Ong J.J.
        • Ma X.
        • Fairley C.K.
        • Latt P.M.
        • Jing J.
        • et al.
        Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
        Hum Vaccin Immunother. 2018; 14: 3010-3018
        • Harder T.
        • Wichmann O.
        • Klug S.J.
        • van der Sande M.A.B.
        • Wiese-Posselt M.
        Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.
        BMC Med. 2018; 16: 110
      2. C.E. Depuydt, G.G.G. Donders, L. Verstraete, M. Berth, D. Vanden Broeck, J. Beert, G. Salembier, E. Bosmans, W. Ombelet, Infectious human Papillomavirus virions in semen reduce clinical pregnancy rates in women undergoing intra-uterine insemination (submitted).

        • Kim J.J.
        • Goldie S.J.
        Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
        BMJ. 2009; 339: b3884
        • Ng S.S.
        • Hutubessy R.
        • Chaiyakunapruk N.
        Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine, gender-neutral and multiple age cohort vaccination.
        Vaccine. 2018; 36: 2529-2544
        • European Board and College of Obstetrics and Gynaecology (EBCOG)
        Standards of care for women’s health in Europe.